

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 204, 206, 208, 401, and 402 as
6 follows:

7 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

8 Sec. 204. (a) The controlled substances listed in this
9 Section are included in Schedule I.

10 (b) Unless specifically excepted or unless listed in
11 another schedule, any of the following opiates, including their
12 isomers, esters, ethers, salts, and salts of isomers, esters,
13 and ethers, whenever the existence of such isomers, esters,
14 ethers and salts is possible within the specific chemical
15 designation:

16 (1) Acetylmethadol;

17 (1.1) Acetyl-alpha-methylfentanyl

18 (N-[1-(1-methyl-2-phenethyl)-
19 4-piperidinyl]-N-phenylacetamide);

20 (2) Allylprodine;

21 (3) Alphacetylmethadol, except
22 levo-alphacetylmethadol (also known as levo-alpha-
23 acetylmethadol, levomethadyl acetate, or LAAM);

- 1 (4) Alphameprodine;
- 2 (5) Alphamethadol;
- 3 (6) Alpha-methylfentanyl
- 4 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
- 5 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
- 6 propanilido) piperidine;
- 7 (6.1) Alpha-methylthiofentanyl
- 8 (N-[1-methyl-2-(2-thienyl)ethyl-
- 9 4-piperidinyl]-N-phenylpropanamide);
- 10 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
- 11 (7.1) PEPAP
- 12 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 13 (8) Benzethidine;
- 14 (9) Betacetylmethadol;
- 15 (9.1) Beta-hydroxyfentanyl
- 16 (N-[1-(2-hydroxy-2-phenethyl)-
- 17 4-piperidinyl]-N-phenylpropanamide);
- 18 (10) Betameprodine;
- 19 (11) Betamethadol;
- 20 (12) Betaprodine;
- 21 (13) Clonitazene;
- 22 (14) Dextromoramide;
- 23 (15) Diampromide;
- 24 (16) Diethylthiambutene;
- 25 (17) Difenoazin;
- 26 (18) Dimenoxadol;

- 1 (19) Dimepheptanol;
- 2 (20) Dimethylthiambutene;
- 3 (21) Dioxaphetylbutyrate;
- 4 (22) Dipipanone;
- 5 (23) Ethylmethylthiambutene;
- 6 (24) Etonitazene;
- 7 (25) Etoxeridine;
- 8 (26) Furethidine;
- 9 (27) Hydroxpethidine;
- 10 (28) Ketobemidone;
- 11 (29) Levomoramide;
- 12 (30) Levophenacylmorphane;
- 13 (31) 3-Methylfentanyl
- 14 (N-[3-methyl-1-(2-phenylethyl)-
- 15 4-piperidyl]-N-phenylpropanamide);
- 16 (31.1) 3-Methylthiofentanyl
- 17 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 18 4-piperidinyl]-N-phenylpropanamide);
- 19 (32) Morpheridine;
- 20 (33) Noracymethadol;
- 21 (34) Norlevorphanol;
- 22 (35) Normethadone;
- 23 (36) Norpipanone;
- 24 (36.1) Para-fluorofentanyl
- 25 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 26 4-piperidinyl]propanamide);

- 1 (37) Phenadoxone;
- 2 (38) Phenampromide;
- 3 (39) Phenomorphan;
- 4 (40) Phenoperidine;
- 5 (41) Piritramide;
- 6 (42) Proheptazine;
- 7 (43) Properidine;
- 8 (44) Propiram;
- 9 (45) Racemoramide;
- 10 (45.1) Thiofentanyl
- 11 (N-phenyl-N-[1-(2-thienyl)ethyl-
- 12 4-piperidinyl]-propanamide);
- 13 (46) Tilidine;
- 14 (47) Trimeperidine;
- 15 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 16 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 17 N-phenylpropanamide);
- 18 (49) Furanyl fentanyl (FU-F);
- 19 (50) Butyryl fentanyl;
- 20 (51) Valeryl fentanyl;
- 21 (52) Acetyl fentanyl;
- 22 (53) Beta-hydroxy-thiofentanyl;
- 23 (54) 3,4-dichloro-N-[2-
- 24 (dimethylamino)cyclohexyl]-N-
- 25 methylbenzamide (U-47700);
- 26 (55) 4-chloro-N-[1-[2-

1 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
2 benzenesulfonamide (W-18);
3 (56) 4-chloro-N-[1-(2-phenylethyl)
4 -2-piperidinylidene]-benzenesulfonamide (W-15);
5 (57) acrylfentanyl (acryloylfentanyl).

6 (c) Unless specifically excepted or unless listed in
7 another schedule, any of the following opium derivatives, its
8 salts, isomers and salts of isomers, whenever the existence of
9 such salts, isomers and salts of isomers is possible within the
10 specific chemical designation:

- 11 (1) Acetorphine;
- 12 (2) Acetyldihydrocodeine;
- 13 (3) Benzylmorphine;
- 14 (4) Codeine methylbromide;
- 15 (5) Codeine-N-Oxide;
- 16 (6) Cyprenorphine;
- 17 (7) Desomorphine;
- 18 (8) Diacetyldihydromorphine (Dihydroheroin);
- 19 (9) Dihydromorphine;
- 20 (10) Drotebanol;
- 21 (11) Etorphine (except hydrochloride salt);
- 22 (12) Heroin;
- 23 (13) Hydromorphenol;
- 24 (14) Methyldesorphine;
- 25 (15) Methyldihydromorphine;
- 26 (16) Morphine methylbromide;

1 (17) Morphine methylsulfonate;

2 (18) Morphine-N-Oxide;

3 (19) Myrophine;

4 (20) Nicocodeine;

5 (21) Nicomorphine;

6 (22) Normorphine;

7 (23) Pholcodine;

8 (24) Thebacon.

9 (d) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 hallucinogenic substances, or which contains any of its salts,
13 isomers and salts of isomers, whenever the existence of such
14 salts, isomers, and salts of isomers is possible within the
15 specific chemical designation (for the purposes of this
16 paragraph only, the term "isomer" includes the optical,
17 position and geometric isomers):

18 (1) 3,4-methylenedioxyamphetamine

19 (alpha-methyl, 3,4-methylenedioxyphenethylamine,
20 methylenedioxyamphetamine, MDA);

21 (1.1) Alpha-ethyltryptamine

22 (some trade or other names: etryptamine;

23 MONASE; alpha-ethyl-1H-indole-3-ethanamine;

24 3-(2-aminobutyl)indole; a-ET; and AET);

25 (2) 3,4-methylenedioxymethamphetamine (MDMA);

26 (2.1) 3,4-methylenedioxy-N-ethylamphetamine

1 (also known as: N-ethyl-alpha-methyl-
2 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
3 and MDEA);

4 (2.2) N-Benzylpiperazine (BZP);

5 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);

6 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);

7 (4) 3,4,5-trimethoxyamphetamine (TMA);

8 (5) (Blank);

9 (6) Diethyltryptamine (DET);

10 (7) Dimethyltryptamine (DMT);

11 (7.1) 5-Methoxy-diallyltryptamine;

12 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

13 (9) Ibogaine (some trade and other names:
14 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
15 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
16 indole; Tabernanthe iboga);

17 (10) Lysergic acid diethylamide;

18 (10.1) Salvinorin A;

19 (10.5) Salvia divinorum (meaning all parts of the plant
20 presently classified botanically as Salvia divinorum,
21 whether growing or not, the seeds thereof, any extract from
22 any part of that plant, and every compound, manufacture,
23 salts, isomers, and salts of isomers whenever the existence
24 of such salts, isomers, and salts of isomers is possible
25 within the specific chemical designation, derivative,
26 mixture, or preparation of that plant, its seeds or

1 extracts);

2 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

3 (12) Peyote (meaning all parts of the plant presently
4 classified botanically as *Lophophora williamsii* Lemaire,
5 whether growing or not, the seeds thereof, any extract from
6 any part of that plant, and every compound, manufacture,
7 salts, derivative, mixture, or preparation of that plant,
8 its seeds or extracts);

9 (13) N-ethyl-3-piperidyl benzilate (JB 318);

10 (14) N-methyl-3-piperidyl benzilate;

11 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
12 (also known as N-hydroxy-alpha-methyl-
13 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

14 (15) Parahexyl; some trade or other names:
15 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
16 dibenzo (b,d) pyran; Synhexyl;

17 (16) Psilocybin;

18 (17) Psilocyn;

19 (18) Alpha-methyltryptamine (AMT);

20 (19) 2,5-dimethoxyamphetamine
21 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

22 (20) 4-bromo-2,5-dimethoxyamphetamine
23 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
24 4-bromo-2,5-DMA);

25 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

26 Some trade or other names: 2-(4-bromo-

1 2,5-dimethoxyphenyl)-1-aminoethane;
2 alpha-desmethyl DOB, 2CB, Nexus;
3 (21) 4-methoxyamphetamine
4 (4-methoxy-alpha-methylphenethylamine;
5 paramethoxyamphetamine; PMA);
6 (22) (Blank);
7 (23) Ethylamine analog of phencyclidine.
8 Some trade or other names:
9 N-ethyl-1-phenylcyclohexylamine,
10 (1-phenylcyclohexyl) ethylamine,
11 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
12 (24) Pyrrolidine analog of phencyclidine. Some trade
13 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
14 PHP;
15 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
16 (26) 2,5-dimethoxy-4-ethylamphetamine
17 (another name: DOET);
18 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
19 (another name: TCPy);
20 (28) (Blank);
21 (29) Thiophene analog of phencyclidine (some trade
22 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
23 2-thienyl analog of phencyclidine; TPCP; TCP);
24 (29.1) Benzothiophene analog of phencyclidine Some
25 trade or other names: BTCP or benocyclidine;
26 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

1 (30) Bufotenine (some trade or other names:

2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

3 3-(2-dimethylaminoethyl)-5-indolol;

4 5-hydroxy-N,N-dimethyltryptamine;

5 N,N-dimethylserotonin; mappine);

6 (31) (Blank); ~~1-Pentyl-3-(1-naphthoyl)indole~~

7 ~~Some trade or other names: JWH-018;~~

8 (32) (Blank); ~~1-Butyl-3-(1-naphthoyl)indole~~

9 ~~Some trade or other names: JWH-073;~~

10 (33) (Blank); ~~1-[(5-fluoropentyl)-1H-indol-3-yl]-~~

11 ~~(2-iodophenyl)methanone~~

12 ~~Some trade or other names: AM-694;~~

13 (34) (Blank); ~~2-[(1R,3S)-3-hydroxycyclohexyl]-5-~~

14 ~~(2-methyloctan-2-yl)phenol~~

15 ~~Some trade or other names: CP-47,497~~

16 ~~and its C6, C8 and C9 homologs;~~

17 (34.5) (Blank); ~~2-[(1R,3S)-3-hydroxycyclohexyl]-5-~~

18 ~~(2-methyloctan-2-yl)phenol), where side chain n=5;~~

19 ~~and homologues where side chain n=4, 6, or 7; Some~~

20 ~~trade or other names: CP-47,497;~~

21 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

22 (2-methyloctan-2-yl)-6a,7,

23 10,10a-tetrahydrobenzo[c]chromen-1-ol

24 Some trade or other names: HU-210;

25 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-

26 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-

1 tetrahydrobenzo[c]chromen-1-ol, its isomers,
2 salts, and salts of isomers; Some trade or other
3 names: HU-210, Dexanabinol;

4 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
5 6,6-dimethyl-3-(2-methyloctan-2-yl)-
6 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
7 Some trade or other names: HU-211;

8 (37) (Blank); ~~(2-methyl-1-propyl-1H-indol-~~
9 ~~3-yl)-1-naphthalenyl-methanone~~
10 ~~Some trade or other names: JWH-015;~~

11 (38) (Blank); ~~4-methoxynaphthalen-1-yl-~~
12 ~~(1-pentylindol-3-yl)-methanone~~
13 ~~Some trade or other names: JWH-081;~~

14 (39) (Blank); ~~1-Pentyl-3-(4-methyl-1-naphthoyl)indole~~
15 ~~Some trade or other names: JWH-122;~~

16 (40) (Blank); ~~2-(2-methylphenyl)-1-(1-pentyl-~~
17 ~~1H-indol-3-yl)-ethanone~~
18 ~~Some trade or other names: JWH-251;~~

19 (41) (Blank); ~~1-(2-cyclohexylethyl)-3-~~
20 ~~(2-methoxyphenylacetyl)indole~~
21 ~~Some trade or other names: RCS-8, BTW-8 and SR-18;~~

22 (42) Any compound structurally derived from
23 3-(1-naphthoyl)indole or 1H-indol-3-yl-
24 (1-naphthyl)methane by substitution at the
25 nitrogen atom of the indole ring by alkyl, haloalkyl,
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,

1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
2 or 2-(4-morpholinyl)ethyl whether or not further
3 substituted in the indole ring to any extent, whether
4 or not substituted in the naphthyl ring to any extent.
5 Examples of this structural class include, but are
6 not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
7 and JWH-185;

8 (43) Any compound structurally derived from
9 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
10 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
12 aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
13 or 2-(4-morpholinyl)ethyl, whether or not further
14 substituted in the pyrrole ring to any extent, whether
15 or not substituted in the naphthyl ring to any extent.
16 Examples of this structural class include, but are not
17 limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
18 JWH-368;

19 (44) Any compound structurally derived from
20 1-(1-naphthylmethyl)indene by substitution
21 at the 3-position of the indene ring by alkyl, haloalkyl,
22 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
23 halide, alkyl aryl halide, 1-(N-methyl-
24 2-piperidinyl)methyl, or 2-(4-
25 morpholinyl)ethyl whether or not further substituted in
26 the indene ring to any extent, whether or not substituted

1 in the naphthyl ring to any extent. Examples of
2 this structural class include, but are not
3 limited to, JWH-176;

4 (45) Any compound structurally derived from
5 3-phenylacetylindole by substitution at the
6 nitrogen atom of the indole ring with alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
8 halide, alkyl aryl halide, 1-(N-methyl-2-
9 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
10 whether or not further substituted in the indole ring
11 to any extent, whether or not substituted in the phenyl
12 ring to any extent. Examples of this structural
13 class include, but are not limited to, JWH-167,
14 JWH-250, JWH-251, and RCS-8;

15 (46) Any compound structurally derived from
16 2-(3-hydroxycyclohexyl)phenol by substitution
17 at the 5-position of the phenolic ring by alkyl,
18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
19 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
20 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
21 whether or not substituted in the cyclohexyl ring to any
22 extent. Examples of this structural class
23 include, but are not limited to, CP 47,
24 497 and its C8 homologue (cannabicyclohexanol);

25 (46.1) Any compound structurally
26 derived from Benzoylindoles: ~~Any compound~~

1 ~~containing a~~ 3-(benzoyl) indole ~~structure~~ with
2 substitution at the nitrogen atom of the
3 indole ring by an alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl,
5 aryl halide, alkyl aryl halide,
6 1-(N-methyl-2-piperidinyl)methyl,
7 or 2-(4-morpholinyl)ethyl group
8 whether or not further substituted
9 in the indole ring to any extent and
10 whether or not substituted in the phenyl ring
11 to any extent. Examples of this structural class
12 include, but are not limited, to AM-630,
13 AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;
14 (47) (Blank); ~~3,4-Methylenedioxymethcathinone~~
15 ~~Some trade or other names: Methylone;~~
16 (48) (Blank); ~~3,4-Methylenedioxypropylvalerone~~
17 ~~Some trade or other names: MDPV;~~
18 (49) (Blank); ~~4-Methylmethcathinone~~
19 ~~Some trade or other names: Mephedrone;~~
20 (50) (Blank); ~~4-methoxymethcathinone;~~
21 (51) (Blank); ~~4-Fluoromethcathinone;~~
22 (52) (Blank); ~~3-Fluoromethcathinone;~~
23 (53) 2,5-Dimethoxy-4-(n)-propylthio-
24 phenethylamine;
25 Some trade or other names: 2C-T-7;
26 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine

1 Some trade or other names: 2C-E;

2 (53.2) 2,5-dimethoxy-4-methylphenethylamine

3 Some trade or other names: 2C-D;

4 (53.3) 4-chloro-2,5-dimethoxyphenethylamine

5 Some trade or other names: 2C-C;

6 (53.4) 4-iodo-2,5-dimethoxyphenethylamine

7 Some trade or other names: 2C-I;

8 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine

9 Some trade or other names: 2C-T-2;

10 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine

11 Some trade or other names: 2C-T-4;

12 (53.7) 2,5-dimethoxyphenethylamine

13 Some trade or other names: 2C-H;

14 (53.8) 2,5-dimethoxy-4-nitrophenethylamine

15 Some trade or other names: 2C-N;

16 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine

17 Some trade or other names: 2C-P;

18 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine

19 Some trade or other names: 2C-G;

20 (53.11) The N-(2-methoxybenzyl) derivative of any 2C

21 phenethylamine referred to in subparagraphs (20.1), (53),

22 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),

23 (53.8), (53.9), and (53.10) including, but not limited to,

24 25I-NBOMe and 25C-NBOMe;

25 (54) 5-Methoxy-N,N-diisopropyltryptamine;

26 (55) (Blank); Pentedrone;

1 (56) (Blank); ~~4-iodo-2,5-dimethoxy-N-((2-methoxy~~
2 ~~phenyl)methyl)-benzeneethanamine~~
3 ~~(trade or other name: 25I-NBOMe)~~;

4 (57) (Blank); ~~4-chloro-2,5-dimethoxy-~~
5 ~~N-[(2-methoxyphenyl)-methyl]-benzeneethanamine~~
6 ~~(trade or other name: 25C-NBOMe)~~;

7 (58) (Blank); ~~4-bromo-2,5-dimethoxy~~
8 ~~N-[(2-methoxyphenyl)-methyl]-benzeneethanamine~~
9 ~~(trade or other name: 25B-NBOMe)~~;

10 (59) 3-cyclopropoylindole with
11 substitution at the nitrogen atom of the
12 indole ring by alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl
14 halide, alkyl aryl halide,
15 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not
17 further substituted on the indole ring
18 to any extent, whether or not substituted
19 on the cyclopropyl ring to any extent:
20 including, but not limited to, XLR11,
21 UR144, FUB-144;

22 (60) 3-adamantoylindole with
23 substitution at the nitrogen atom of the
24 indole ring by alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl,
26 aryl halide, alkyl aryl halide,

1 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not
3 further substituted on the indole ring to
4 any extent, whether or not substituted on
5 the adamantyl ring to any extent: including,
6 but not limited to, AB-001;

7 (61) N-(adamantyl)-indole-3-carboxamide
8 with substitution at the nitrogen atom of the
9 indole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide,
11 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
12 or 2-(4-morpholinyl)ethyl, whether or not further
13 substituted on the indole ring to any extent, whether
14 or not substituted on the adamantyl ring to any
15 extent: including, but not limited to,
16 APICA/2NE-1, STS-135;

17 (62) N-(adamantyl)-indazole-3-carboxamide
18 with substitution at a nitrogen atom of the indazole
19 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
20 cycloalkylethyl, aryl halide, alkyl aryl halide,
21 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further
23 substituted on the indazole ring to any extent,
24 whether or not substituted on the adamantyl
25 ring to any extent: including, but not limited
26 to, AKB48, 5F-AKB48;

1 (63) 1H-indole-3-carboxylic acid 8-quinolinyl
2 ester with substitution at the nitrogen atom of the
3 indole ring by alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
5 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further
7 substituted on the indole ring to any extent,
8 whether or not substituted on the quinoline ring
9 to any extent: including, but not limited to, PB22,
10 5F-PB22, FUB-PB-22;

11 (64) 3-(1-naphthoyl)indazole with
12 substitution at the nitrogen atom of the
13 indazole ring by alkyl, haloalkyl,
14 alkenyl, cycloalkylmethyl, cycloalkylethyl,
15 aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further
18 substituted on the indazole ring to any extent,
19 whether or not substituted on the naphthyl ring
20 to any extent: including, but not limited to,
21 THJ-018, THJ-2201;

22 (65) 2-(1-naphthoyl)benzimidazole with
23 substitution at the nitrogen atom of the benzimidazole
24 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25 cycloalkylethyl, aryl halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further
2 substituted on the benzimidazole ring to any extent,
3 whether or not substituted on the naphthyl ring to
4 any extent: including, but not limited to, FUBIMINA;

5 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)
6 -1H-indazole-3-carboxamide with substitution on the
7 nitrogen atom of the indazole ring by alkyl,
8 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
10 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
11 whether or not further substituted on the indazole
12 ring to any extent: including, but not limited to,
13 AB-PINACA, AB-FUBINACA, AB-CHMINACA;

14 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-
15 2-yl)-1H-indazole-3-carboxamide with substitution
16 on the nitrogen atom of the indazole ring by alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether
20 or not further substituted on the indazole ring to any
21 extent: including, but not limited to, ADB-PINACA,
22 ADB-FUBINACA;

23 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-
24 1H-indole-3-carboxamide with substitution on the nitrogen
25 atom of the indole ring by alkyl, haloalkyl, alkenyl,
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl

1 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl, whether or not further
3 substituted on the indole ring to any extent:
4 including, but not limited to, ADBICA, 5F-ADBICA;

5 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-
6 1H-indole-3-carboxamide with substitution on the
7 nitrogen atom of the indole ring by alkyl, haloalkyl,
8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
9 halide, alkyl aryl halide, 1-(N-methyl-2-
10 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
11 whether or not further substituted on the indole
12 ring to any extent: including, but not limited
13 to, ABICA, 5F-ABICA;

14 (70) Methyl 2-(1H-indazole-3-carboxamido)-
15 3-methylbutanoate with substitution on the nitrogen
16 atom of the indazole ring by alkyl, haloalkyl,
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
18 halide, alkyl aryl halide, 1-(N-methyl-2-
19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
20 whether or not further substituted on the indazole
21 ring to any extent: including, but not limited to, AMB,
22 5F-AMB.

23 (71) Methyl 2-(1H-indazole-3-carboxamido)
24 -3,3-dimethylbutanoate with substitution on the nitrogen
25 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl

1 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
2 (4-morpholinyl)ethyl, whether or not further substituted
3 on the indazole ring to any extent: including, but not
4 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

5 (72) Methyl 2-(1H-indole-3-carboxamido)-
6 3-methylbutanoate with substitution on the nitrogen atom
7 of the indole ring by alkyl, haloalkyl, alkenyl,
8 cycloalkylmethyl, cycloalkylethyl, aryl halide,
9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
10 or 2-(4-morpholinyl)ethyl, whether or not further
11 substituted on the indazole ring to any extent:
12 including, but not limited to, MMB018, MMB2201,
13 and AMB-CHMICA;

14 (73) Methyl 2-(1H-indole-3-
15 carboxamido)-3,3-dimethylbutanoate with substitution
16 on the nitrogen atom of the indole ring by alkyl,
17 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
19 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
20 whether or not further substituted on the
21 indazole ring to any extent: including, but
22 not limited to, MDMB-CHMICA;

23 (74) N-(1-Amino-1-oxo-3-phenylpropan
24 -2-yl) -1H-indazole-3-carboxamide with
25 substitution on the nitrogen atom of the indazole
26 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

1 cycloalkylethyl, aryl halide, alkyl aryl halide,
2 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
3 morpholinyl)ethyl, whether or not further
4 substituted on the indazole ring to any
5 extent: including, but not limited to, APP-CHMINACA,
6 5-fluoro-APP-PINACA;

7 (75) N-(1-Amino-1-oxo-3-phenylpropan
8 -2-yl)-1H-indole-3-carboxamide with substitution on
9 the nitrogen atom of the indole ring by alkyl,
10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
11 aryl halide, alkyl aryl halide, 1-(N-methyl-2-
12 piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
13 whether or not further substituted on the indazole
14 ring to any extent: including, but not limited to,
15 APP-PICA and 5-fluoro-APP-PICA;

16 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
17 4-AcO-DMT;

18 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade
19 name 5-MeO-MIPT;

20 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

21 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

22 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT);

23 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
24 (4-HO-MiPT);

25 (82) Fluorophenylpiperazine;

26 (83) Methoxetamine;

1 (84) 1-(Ethylamino)-2-phenylpropan-2-
2 one (iso-ethcathinone).

3 (e) Unless specifically excepted or unless listed in
4 another schedule, any material, compound, mixture, or
5 preparation which contains any quantity of the following
6 substances having a depressant effect on the central nervous
7 system, including its salts, isomers, and salts of isomers
8 whenever the existence of such salts, isomers, and salts of
9 isomers is possible within the specific chemical designation:

- 10 (1) mecloqualone;
11 (2) methaqualone; and
12 (3) gamma hydroxybutyric acid.

13 (f) Unless specifically excepted or unless listed in
14 another schedule, any material, compound, mixture, or
15 preparation which contains any quantity of the following
16 substances having a stimulant effect on the central nervous
17 system, including its salts, isomers, and salts of isomers:

- 18 (1) Fenethylamine;
19 (2) N-ethylamphetamine;
20 (3) Aminorex (some other names:
21 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
22 4-5-dihydro-5-phenyl-2-oxazolamine) and its
23 salts, optical isomers, and salts of optical isomers;
24 (4) Methcathinone (some other names:
25 2-methylamino-1-phenylpropan-1-one;
26 Ephedrone; 2-(methylamino)-propionophenone;

1 alpha-(methylamino)propiofenone; N-methylcathinone;
2 methycathinone; Monomethylpropion; UR 1431) and its
3 salts, optical isomers, and salts of optical isomers;

4 (5) Cathinone (some trade or other names:
5 2-aminopropiofenone; alpha-aminopropiofenone;
6 2-amino-1-phenyl-propanone; norephedrone);

7 (6) N,N-dimethylamphetamine (also known as:
8 N,N-alpha-trimethyl-benzeneethanamine;
9 N,N-alpha-trimethylphenethylamine);

10 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
11 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

12 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

13 (9) Halogenated amphetamines and
14 methamphetamines - any compound derived from either
15 amphetamine or methamphetamine through the substitution
16 of a halogen on the phenyl ring, including, but not
17 limited to, 2-fluoroamphetamine, 3-
18 fluoroamphetamine and 4-fluoroamphetamine;

19 (10) Aminopropylbenzofuran (APB):
20 including 4-(2-Aminopropyl) benzofuran, 5-
21 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
22 benzofuran, and 7-(2-Aminopropyl) benzofuran;

23 (11) Aminopropyl-dihydrobenzofuran (APDB):
24 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
25 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
26 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,

1 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
2 (12) Methylaminopropylbenzofuran
3 (MAPB): including 4-(2-methylaminopropyl)
4 benzofuran, 5-(2-methylaminopropyl)benzofuran,
5 6-(2-methylaminopropyl)benzofuran
6 and 7-(2-methylaminopropyl)benzofuran.

7 (g) Temporary listing of substances subject to emergency
8 scheduling. Any material, compound, mixture, or preparation
9 that contains any quantity of the following substances:

10 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
11 (benzylfentanyl), its optical isomers, isomers, salts,
12 and salts of isomers;

13 (2) N-[1(2-thienyl)
14 methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
15 its optical isomers, salts, and salts of isomers.

16 (h) Synthetic cathinones. Unless specifically excepted,
17 any chemical compound which is not approved by the United
18 States Food and Drug Administration or, if approved, is not
19 dispensed or possessed in accordance with State or federal law,
20 not including bupropion, structurally derived from
21 2-aminopropan-1-one by substitution at the 1-position with
22 either phenyl, naphthyl, or thiophene ring systems, whether or
23 not the compound is further modified in one or more of the
24 following ways:

25 (1) by substitution in the ring system to
26 any extent with alkyl, alkylendioxy, alkoxy,

1 haloalkyl, hydroxyl, or halide substituents, whether
2 or not further substituted in the ring system
3 by one or more other univalent substituents.
4 Examples of this class include, but are not
5 limited to, 3,4-Methylenedioxcathinone
6 (bk-MDA);

7 (2) by substitution at the 3-position
8 with an acyclic alkyl substituent. Examples of
9 this class include, but are not limited to,
10 2-methylamino-1-phenylbutan-1-one
11 (buphedrone); or

12 (3) by substitution at the 2-amino nitrogen
13 atom with alkyl, dialkyl, benzyl, or methoxybenzyl
14 groups, or by inclusion of the 2-amino nitrogen atom
15 in a cyclic structure. Examples of this class include,
16 but are not limited to, Dimethylcathinone, Ethcathinone,
17 and α -Pyrrolidinopropiophenone (α -PPP).

18 (Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised
19 10-25-16.)

20 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)

21 Sec. 206. (a) The controlled substances listed in this
22 Section are included in Schedule II.

23 (b) Unless specifically excepted or unless listed in
24 another schedule, any of the following substances whether
25 produced directly or indirectly by extraction from substances

1 of vegetable origin, or independently by means of chemical
2 synthesis, or by combination of extraction and chemical
3 synthesis:

4 (1) Opium and opiates, and any salt, compound,
5 derivative or preparation of opium or opiate, excluding
6 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
7 nalmefene, naloxone, and naltrexone, and their respective
8 salts, but including the following:

9 (i) Raw Opium;

10 (ii) Opium extracts;

11 (iii) Opium fluid extracts;

12 (iv) Powdered opium;

13 (v) Granulated opium;

14 (vi) Tincture of opium;

15 (vii) Codeine;

16 (viii) Ethylmorphine;

17 (ix) Etorphine Hydrochloride;

18 (x) Hydrocodone;

19 (xi) Hydromorphone;

20 (xii) Metopon;

21 (xiii) Morphine;

22 (xiii.5) 6-Monoacetylmorphine;

23 (xiv) Oxycodone;

24 (xv) Oxymorphone;

25 (xv.5) Tapentadol;

26 (xvi) Thebaine;

1 (xvii) Thebaine-derived butorphanol.

2 (xviii) Methorphan ~~Dextromethorphan~~, except drug
3 products containing dextromethorphan that may be
4 dispensed pursuant to a prescription order of a
5 practitioner and are sold in compliance with the safety
6 and labeling standards as set forth by the United
7 States Food and Drug Administration, or drug products
8 containing dextromethorphan that are sold in solid,
9 tablet, liquid, capsule, powder, thin film, or gel form
10 and which are formulated, packaged, and sold in dosages
11 and concentrations for use as an over-the-counter drug
12 product. For the purposes of this Section,
13 "over-the-counter drug product" means a drug that is
14 available to consumers without a prescription and sold
15 in compliance with the safety and labeling standards as
16 set forth by the United States Food and Drug
17 Administration.

18 (2) Any salt, compound, isomer, derivative or
19 preparation thereof which is chemically equivalent or
20 identical with any of the substances referred to in
21 subparagraph (1), but not including the isoquinoline
22 alkaloids of opium;

23 (3) Opium poppy and poppy straw;

24 (4) Coca leaves and any salt, compound, isomer, salt of
25 an isomer, derivative, or preparation of coca leaves
26 including cocaine or ecgonine, and any salt, compound,

1 isomer, derivative, or preparation thereof which is
2 chemically equivalent or identical with any of these
3 substances, but not including decocainized coca leaves or
4 extractions of coca leaves which do not contain cocaine or
5 ecgonine (for the purpose of this paragraph, the term
6 "isomer" includes optical, positional and geometric
7 isomers);

8 (5) Concentrate of poppy straw (the crude extract of
9 poppy straw in either liquid, solid or powder form which
10 contains the phenanthrine alkaloids of the opium poppy).

11 (c) Unless specifically excepted or unless listed in
12 another schedule any of the following opiates, including their
13 isomers, esters, ethers, salts, and salts of isomers, whenever
14 the existence of these isomers, esters, ethers and salts is
15 possible within the specific chemical designation, dextrorphan
16 excepted:

17 (1) Alfentanil;

18 (1.1) Carfentanil;

19 (1.2) Thiafentanil;

20 (2) Alphaprodine;

21 (3) Anileridine;

22 (4) Bezitramide;

23 (5) Bulk Dextropropoxyphene (non-dosage forms);

24 (6) Dihydrocodeine;

25 (7) Diphenoxylate;

26 (8) Fentanyl;

- 1 (9) Sufentanil;
- 2 (9.5) Remifentanil;
- 3 (10) Isomethadone;
- 4 (11) (Blank); ~~Levomethorphan;~~
- 5 (12) Levorphanol (Levorphan);
- 6 (13) Metazocine;
- 7 (14) Methadone;
- 8 (15) Methadone-Intermediate,
- 9 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
- 10 (16) Moramide-Intermediate,
- 11 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
- 12 acid;
- 13 (17) Pethidine (meperidine);
- 14 (18) Pethidine-Intermediate-A,
- 15 4-cyano-1-methyl-4-phenylpiperidine;
- 16 (19) Pethidine-Intermediate-B,
- 17 ethyl-4-phenylpiperidine-4-carboxylate;
- 18 (20) Pethidine-Intermediate-C,
- 19 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 20 (21) Phenazocine;
- 21 (22) Piminodine;
- 22 (23) Racemethorphan;
- 23 (24) (Blank); ~~Racemorphan;~~
- 24 (25) Levo-alpha-acetylmethadol (some other names:
- 25 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
- 26 (d) Unless specifically excepted or unless listed in

1 another schedule, any material, compound, mixture, or
2 preparation which contains any quantity of the following
3 substances having a stimulant effect on the central nervous
4 system:

5 (1) Amphetamine, its salts, optical isomers, and salts
6 of its optical isomers;

7 (2) Methamphetamine, its salts, isomers, and salts of
8 its isomers;

9 (3) Phenmetrazine and its salts;

10 (4) Methylphenidate;

11 (5) Lisdexamfetamine.

12 (e) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or
14 preparation which contains any quantity of the following
15 substances having a depressant effect on the central nervous
16 system, including its salts, isomers, and salts of isomers
17 whenever the existence of such salts, isomers, and salts of
18 isomers is possible within the specific chemical designation:

19 (1) Amobarbital;

20 (2) Secobarbital;

21 (3) Pentobarbital;

22 (4) Pentazocine;

23 (5) Phencyclidine;

24 (6) Gluthethimide;

25 (7) (Blank).

26 (f) Unless specifically excepted or unless listed in

1 another schedule, any material, compound, mixture, or
2 preparation which contains any quantity of the following
3 substances:

4 (1) Immediate precursor to amphetamine and
5 methamphetamine:

6 (i) Phenylacetone

7 Some trade or other names: phenyl-2-propanone;

8 P2P; benzyl methyl ketone; methyl benzyl ketone.

9 (2) Immediate precursors to phencyclidine:

10 (i) 1-phenylcyclohexylamine;

11 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).

12 (3) Nabilone.

13 (Source: P.A. 97-334, eff. 1-1-12.)

14 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)

15 Sec. 208. (a) The controlled substances listed in this
16 Section are included in Schedule III.

17 (b) Unless specifically excepted or unless listed in
18 another schedule, any material, compound, mixture, or
19 preparation which contains any quantity of the following
20 substances having a stimulant effect on the central nervous
21 system, including its salts, isomers (whether optical
22 position, or geometric), and salts of such isomers whenever the
23 existence of such salts, isomers, and salts of isomers is
24 possible within the specific chemical designation;

25 (1) Those compounds, mixtures, or preparations in

1 dosage unit form containing any stimulant substances
2 listed in Schedule II which compounds, mixtures, or
3 preparations were listed on August 25, 1971, as excepted
4 compounds under Title 21, Code of Federal Regulations,
5 Section 308.32, and any other drug of the quantitative
6 composition shown in that list for those drugs or which is
7 the same except that it contains a lesser quantity of
8 controlled substances;

9 (2) Benzphetamine;

10 (3) Chlorphentermine;

11 (4) Clortermine;

12 (5) Phendimetrazine.

13 (c) Unless specifically excepted or unless listed in
14 another schedule, any material, compound, mixture, or
15 preparation which contains any quantity of the following
16 substances having a potential for abuse associated with a
17 depressant effect on the central nervous system:

18 (1) Any compound, mixture, or preparation containing
19 amobarbital, secobarbital, pentobarbital or any salt
20 thereof and one or more other active medicinal ingredients
21 which are not listed in any schedule;

22 (2) Any suppository dosage form containing
23 amobarbital, secobarbital, pentobarbital or any salt of
24 any of these drugs and approved by the Federal Food and
25 Drug Administration for marketing only as a suppository;

26 (3) Any substance which contains any quantity of a

1 derivative of barbituric acid, or any salt thereof:

2 (3.1) Aprobarbital;

3 (3.2) Butabarbital (secbutabarbital);

4 (3.3) Butalbital;

5 (3.4) Butobarbital (butethal);

6 (4) Chlorhexadol;

7 (5) Methyprylon;

8 (6) Sulfondiethylmethane;

9 (7) Sulfonethylmethane;

10 (8) Sulfonmethane;

11 (9) Lysergic acid;

12 (10) Lysergic acid amide;

13 (10.1) Tiletamine or zolazepam or both, or any salt of
14 either of them.

15 Some trade or other names for a tiletamine-zolazepam
16 combination product: Telazol.

17 Some trade or other names for Tiletamine:

18 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

19 Some trade or other names for zolazepam:

20 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
21 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.

22 (11) Any material, compound, mixture or preparation
23 containing not more than 12.5 milligrams of pentazocine or
24 any of its salts, per 325 milligrams of aspirin;

25 (12) Any material, compound, mixture or preparation
26 containing not more than 12.5 milligrams of pentazocine or

1 any of its salts, per 325 milligrams of acetaminophen;

2 (13) Any material, compound, mixture or preparation
3 containing not more than 50 milligrams of pentazocine or
4 any of its salts plus naloxone HCl USP 0.5 milligrams, per
5 dosage unit;

6 (14) Ketamine;

7 (15) Thiopental.

8 (d) Nalorphine.

9 (d.5) Buprenorphine.

10 (e) Unless specifically excepted or unless listed in
11 another schedule, any material, compound, mixture, or
12 preparation containing limited quantities of any of the
13 following narcotic drugs, or their salts calculated as the free
14 anhydrous base or alkaloid, as set forth below:

15 (1) not more than 1.8 grams of codeine per 100
16 milliliters or not more than 90 milligrams per dosage unit,
17 with an equal or greater quantity of an isoquinoline
18 alkaloid of opium;

19 (2) not more than 1.8 grams of codeine per 100
20 milliliters or not more than 90 milligrams per dosage unit,
21 with one or more active non-narcotic ingredients in
22 recognized therapeutic amounts;

23 (3) (blank); ~~not more than 300 milligrams of~~
24 ~~dihydrocodeinone per 100 milliliters or not more than 15~~
25 ~~milligrams per dosage unit, with a fourfold or greater~~
26 ~~quantity of an isoquinoline alkaloid of opium;~~

1 (4) (blank); ~~not more than 300 milligrams of~~
2 ~~dihydrocodeinone per 100 milliliters or not more than 15~~
3 ~~milligrams per dosage unit, with one or more active,~~
4 ~~non-narcotic ingredients in recognized therapeutic~~
5 ~~amounts;~~

6 (5) not more than 1.8 grams of dihydrocodeine per 100
7 milliliters or not more than 90 milligrams per dosage unit,
8 with one or more active, non-narcotic ingredients in
9 recognized therapeutic amounts;

10 (6) not more than 300 milligrams of ethylmorphine per
11 100 milliliters or not more than 15 milligrams per dosage
12 unit, with one or more active, non-narcotic ingredients in
13 recognized therapeutic amounts;

14 (7) not more than 500 milligrams of opium per 100
15 milliliters or per 100 grams, or not more than 25
16 milligrams per dosage unit, with one or more active,
17 non-narcotic ingredients in recognized therapeutic
18 amounts;

19 (8) not more than 50 milligrams of morphine per 100
20 milliliters or per 100 grams with one or more active,
21 non-narcotic ingredients in recognized therapeutic
22 amounts.

23 (f) Anabolic steroids, except the following anabolic
24 steroids that are exempt:

25 (1) Androgyn L.A.;

26 (2) Andro-Estro 90-4;

- 1 (3) depANDROGYN;
- 2 (4) DEPO-T.E.;
- 3 (5) depTESTROGEN;
- 4 (6) Duomone;
- 5 (7) DURATESTRIN;
- 6 (8) DUO-SPAN II;
- 7 (9) Estratest;
- 8 (10) Estratest H.S.;
- 9 (11) PAN ESTRA TEST;
- 10 (12) Premarin with Methyltestosterone;
- 11 (13) TEST-ESTRO Cypionates;
- 12 (14) Testosterone Cyp 50 Estradiol Cyp 2;
- 13 (15) Testosterone Cypionate-Estradiol Cypionate
- 14 injection; and
- 15 (16) Testosterone Enanthate-Estradiol Valerate
- 16 injection.
- 17 (g) Hallucinogenic substances.
- 18 (1) Dronabinol (synthetic) in sesame oil and
- 19 encapsulated in a soft gelatin capsule in a U.S. Food and
- 20 Drug Administration approved product. Some other names for
- 21 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
- 22 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
- 23 (-)-delta-9-(trans)-tetrahydrocannabinol.
- 24 (2) (Reserved).
- 25 (h) The Department may except by rule any compound,
- 26 mixture, or preparation containing any stimulant or depressant

1 substance listed in subsection (b) from the application of all
2 or any part of this Act if the compound, mixture, or
3 preparation contains one or more active medicinal ingredients
4 not having a stimulant or depressant effect on the central
5 nervous system, and if the admixtures are included therein in
6 combinations, quantity, proportion, or concentration that
7 vitiate the potential for abuse of the substances which have a
8 stimulant or depressant effect on the central nervous system.

9 (Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10;
10 97-334, eff. 1-1-12.)

11 (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)

12 Sec. 401. Manufacture or delivery, or possession with
13 intent to manufacture or deliver, a controlled substance, a
14 counterfeit substance, or controlled substance analog. Except
15 as authorized by this Act, it is unlawful for any person
16 knowingly to manufacture or deliver, or possess with intent to
17 manufacture or deliver, a controlled substance other than
18 methamphetamine and other than bath salts as defined in the
19 Bath Salts Prohibition Act sold or offered for sale in a retail
20 mercantile establishment as defined in Section 16-0.1 of the
21 Criminal Code of 2012, a counterfeit substance, or a controlled
22 substance analog. A violation of this Act with respect to each
23 of the controlled substances listed herein constitutes a single
24 and separate violation of this Act. For purposes of this
25 Section, "controlled substance analog" or "analog" means a

1 substance, other than a controlled substance, which is not
2 approved by the United States Food and Drug Administration or,
3 if approved, is not dispensed or possessed in accordance with
4 State or federal law, and that has a chemical structure
5 substantially similar to that of a controlled substance in
6 Schedule I or II, or that was specifically designed to produce
7 an effect substantially similar to that of a controlled
8 substance in Schedule I or II. Examples of chemical classes in
9 which controlled substance analogs are found include, but are
10 not limited to, the following: phenethylamines, N-substituted
11 piperidines, morphinans, ecgonines, quinazolinones,
12 substituted indoles, and arylcycloalkylamines. For purposes of
13 this Act, a controlled substance analog shall be treated in the
14 same manner as the controlled substance to which it is
15 substantially similar.

16 (a) Any person who violates this Section with respect to
17 the following amounts of controlled or counterfeit substances
18 or controlled substance analogs, notwithstanding any of the
19 provisions of subsections (c), (d), (e), (f), (g) or (h) to the
20 contrary, is guilty of a Class X felony and shall be sentenced
21 to a term of imprisonment as provided in this subsection (a)
22 and fined as provided in subsection (b):

23 (1) (A) not less than 6 years and not more than 30
24 years with respect to 15 grams or more but less than
25 100 grams of a substance containing heroin, or an
26 analog thereof;

1 (B) not less than 9 years and not more than 40
2 years with respect to 100 grams or more but less than
3 400 grams of a substance containing heroin, or an
4 analog thereof;

5 (C) not less than 12 years and not more than 50
6 years with respect to 400 grams or more but less than
7 900 grams of a substance containing heroin, or an
8 analog thereof;

9 (D) not less than 15 years and not more than 60
10 years with respect to 900 grams or more of any
11 substance containing heroin, or an analog thereof;

12 (1.5) (A) not less than 6 years and not more than 30
13 years with respect to 15 grams or more but less than
14 100 grams of a substance containing fentanyl, or an
15 analog thereof;

16 (B) not less than 9 years and not more than 40
17 years with respect to 100 grams or more but less than
18 400 grams of a substance containing fentanyl, or an
19 analog thereof;

20 (C) not less than 12 years and not more than 50
21 years with respect to 400 grams or more but less than
22 900 grams of a substance containing fentanyl, or an
23 analog thereof;

24 (D) not less than 15 years and not more than 60
25 years with respect to 900 grams or more of a substance
26 containing fentanyl, or an analog thereof;

1 (2) (A) not less than 6 years and not more than 30
2 years with respect to 15 grams or more but less than
3 100 grams of a substance containing cocaine, or an
4 analog thereof;

5 (B) not less than 9 years and not more than 40
6 years with respect to 100 grams or more but less than
7 400 grams of a substance containing cocaine, or an
8 analog thereof;

9 (C) not less than 12 years and not more than 50
10 years with respect to 400 grams or more but less than
11 900 grams of a substance containing cocaine, or an
12 analog thereof;

13 (D) not less than 15 years and not more than 60
14 years with respect to 900 grams or more of any
15 substance containing cocaine, or an analog thereof;

16 (3) (A) not less than 6 years and not more than 30
17 years with respect to 15 grams or more but less than
18 100 grams of a substance containing morphine, or an
19 analog thereof;

20 (B) not less than 9 years and not more than 40
21 years with respect to 100 grams or more but less than
22 400 grams of a substance containing morphine, or an
23 analog thereof;

24 (C) not less than 12 years and not more than 50
25 years with respect to 400 grams or more but less than
26 900 grams of a substance containing morphine, or an

1 analog thereof;

2 (D) not less than 15 years and not more than 60
3 years with respect to 900 grams or more of a substance
4 containing morphine, or an analog thereof;

5 (4) 200 grams or more of any substance containing
6 peyote, or an analog thereof;

7 (5) 200 grams or more of any substance containing a
8 derivative of barbituric acid or any of the salts of a
9 derivative of barbituric acid, or an analog thereof;

10 (6) 200 grams or more of any substance containing
11 amphetamine or any salt of an optical isomer of
12 amphetamine, or an analog thereof;

13 (6.5) (blank);

14 (6.6) (blank);

15 (7) (A) not less than 6 years and not more than 30
16 years with respect to: (i) 15 grams or more but less
17 than 100 grams of a substance containing lysergic acid
18 diethylamide (LSD), or an analog thereof, or (ii) 15 or
19 more objects or 15 or more segregated parts of an
20 object or objects but less than 200 objects or 200
21 segregated parts of an object or objects containing in
22 them or having upon them any amounts of any substance
23 containing lysergic acid diethylamide (LSD), or an
24 analog thereof;

25 (B) not less than 9 years and not more than 40
26 years with respect to: (i) 100 grams or more but less

1 than 400 grams of a substance containing lysergic acid
2 diethylamide (LSD), or an analog thereof, or (ii) 200
3 or more objects or 200 or more segregated parts of an
4 object or objects but less than 600 objects or less
5 than 600 segregated parts of an object or objects
6 containing in them or having upon them any amount of
7 any substance containing lysergic acid diethylamide
8 (LSD), or an analog thereof;

9 (C) not less than 12 years and not more than 50
10 years with respect to: (i) 400 grams or more but less
11 than 900 grams of a substance containing lysergic acid
12 diethylamide (LSD), or an analog thereof, or (ii) 600
13 or more objects or 600 or more segregated parts of an
14 object or objects but less than 1500 objects or 1500
15 segregated parts of an object or objects containing in
16 them or having upon them any amount of any substance
17 containing lysergic acid diethylamide (LSD), or an
18 analog thereof;

19 (D) not less than 15 years and not more than 60
20 years with respect to: (i) 900 grams or more of any
21 substance containing lysergic acid diethylamide (LSD),
22 or an analog thereof, or (ii) 1500 or more objects or
23 1500 or more segregated parts of an object or objects
24 containing in them or having upon them any amount of a
25 substance containing lysergic acid diethylamide (LSD),
26 or an analog thereof;

1 (7.5) (A) not less than 6 years and not more than 30
2 years with respect to: (i) 15 grams or more but less
3 than 100 grams of a substance listed in paragraph (1),
4 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
5 (21), (25), or (26) of subsection (d) of Section 204,
6 or an analog or derivative thereof, or (ii) 15 or more
7 pills, tablets, caplets, capsules, or objects but less
8 than 200 pills, tablets, caplets, capsules, or objects
9 containing in them or having upon them any amounts of
10 any substance listed in paragraph (1), (2), (2.1),
11 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
12 (26) of subsection (d) of Section 204, or an analog or
13 derivative thereof;

14 (B) not less than 9 years and not more than 40
15 years with respect to: (i) 100 grams or more but less
16 than 400 grams of a substance listed in paragraph (1),
17 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
18 (21), (25), or (26) of subsection (d) of Section 204,
19 or an analog or derivative thereof, or (ii) 200 or more
20 pills, tablets, caplets, capsules, or objects but less
21 than 600 pills, tablets, caplets, capsules, or objects
22 containing in them or having upon them any amount of
23 any substance listed in paragraph (1), (2), (2.1),
24 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
25 (26) of subsection (d) of Section 204, or an analog or
26 derivative thereof;

1 (C) not less than 12 years and not more than 50
2 years with respect to: (i) 400 grams or more but less
3 than 900 grams of a substance listed in paragraph (1),
4 (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
5 (21), (25), or (26) of subsection (d) of Section 204,
6 or an analog or derivative thereof, or (ii) 600 or more
7 pills, tablets, caplets, capsules, or objects but less
8 than 1,500 pills, tablets, caplets, capsules, or
9 objects containing in them or having upon them any
10 amount of any substance listed in paragraph (1), (2),
11 (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21),
12 (25), or (26) of subsection (d) of Section 204, or an
13 analog or derivative thereof;

14 (D) not less than 15 years and not more than 60
15 years with respect to: (i) 900 grams or more of any
16 substance listed in paragraph (1), (2), (2.1), (2.2),
17 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
18 subsection (d) of Section 204, or an analog or
19 derivative thereof, or (ii) 1,500 or more pills,
20 tablets, caplets, capsules, or objects containing in
21 them or having upon them any amount of a substance
22 listed in paragraph (1), (2), (2.1), (2.2), (3),
23 (14.1), (19), (20), (20.1), (21), (25), or (26) of
24 subsection (d) of Section 204, or an analog or
25 derivative thereof;

26 (8) 30 grams or more of any substance containing

1 pentazocine or any of the salts, isomers and salts of
2 isomers of pentazocine, or an analog thereof;

3 (9) 30 grams or more of any substance containing
4 methaqualone or any of the salts, isomers and salts of
5 isomers of methaqualone, or an analog thereof;

6 (10) 30 grams or more of any substance containing
7 phencyclidine or any of the salts, isomers and salts of
8 isomers of phencyclidine (PCP), or an analog thereof;

9 (10.5) 30 grams or more of any substance containing
10 ketamine or any of the salts, isomers and salts of isomers
11 of ketamine, or an analog thereof;

12 (10.6) 100 grams or more of any substance containing
13 hydrocodone, or any of the salts, isomers and salts of
14 isomers of hydrocodone, or an analog thereof;

15 (10.7) (blank); ~~100 grams or more of any substance~~
16 ~~containing dihydrocodeinone, or any of the salts, isomers~~
17 ~~and salts of isomers of dihydrocodeinone, or an analog~~
18 ~~thereof;~~

19 (10.8) 100 grams or more of any substance containing
20 dihydrocodeine, or any of the salts, isomers and salts of
21 isomers of dihydrocodeine, or an analog thereof;

22 (10.9) 100 grams or more of any substance containing
23 oxycodone, or any of the salts, isomers and salts of
24 isomers of oxycodone, or an analog thereof;

25 (11) 200 grams or more of any substance containing any
26 other controlled substance classified in Schedules I or II,

1 or an analog thereof, which is not otherwise included in
2 this subsection.

3 (b) Any person sentenced with respect to violations of
4 paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
5 involving 100 grams or more of the controlled substance named
6 therein, may in addition to the penalties provided therein, be
7 fined an amount not more than \$500,000 or the full street value
8 of the controlled or counterfeit substance or controlled
9 substance analog, whichever is greater. The term "street value"
10 shall have the meaning ascribed in Section 110-5 of the Code of
11 Criminal Procedure of 1963. Any person sentenced with respect
12 to any other provision of subsection (a), may in addition to
13 the penalties provided therein, be fined an amount not to
14 exceed \$500,000.

15 (b-1) Excluding violations of this Act when the controlled
16 substance is fentanyl, any person sentenced to a term of
17 imprisonment with respect to violations of Section 401, 401.1,
18 405, 405.1, 405.2, or 407, when the substance containing the
19 controlled substance contains any amount of fentanyl, 3 years
20 shall be added to the term of imprisonment imposed by the
21 court, and the maximum sentence for the offense shall be
22 increased by 3 years.

23 (c) Any person who violates this Section with regard to the
24 following amounts of controlled or counterfeit substances or
25 controlled substance analogs, notwithstanding any of the
26 provisions of subsections (a), (b), (d), (e), (f), (g) or (h)

1 to the contrary, is guilty of a Class 1 felony. The fine for
2 violation of this subsection (c) shall not be more than
3 \$250,000:

4 (1) 1 gram or more but less than 15 grams of any
5 substance containing heroin, or an analog thereof;

6 (1.5) 1 gram or more but less than 15 grams of any
7 substance containing fentanyl, or an analog thereof;

8 (2) 1 gram or more but less than 15 grams of any
9 substance containing cocaine, or an analog thereof;

10 (3) 10 grams or more but less than 15 grams of any
11 substance containing morphine, or an analog thereof;

12 (4) 50 grams or more but less than 200 grams of any
13 substance containing peyote, or an analog thereof;

14 (5) 50 grams or more but less than 200 grams of any
15 substance containing a derivative of barbituric acid or any
16 of the salts of a derivative of barbituric acid, or an
17 analog thereof;

18 (6) 50 grams or more but less than 200 grams of any
19 substance containing amphetamine or any salt of an optical
20 isomer of amphetamine, or an analog thereof;

21 (6.5) (blank);

22 (7) (i) 5 grams or more but less than 15 grams of any
23 substance containing lysergic acid diethylamide (LSD), or
24 an analog thereof, or (ii) more than 10 objects or more
25 than 10 segregated parts of an object or objects but less
26 than 15 objects or less than 15 segregated parts of an

1 object containing in them or having upon them any amount of
2 any substance containing lysergic acid diethylamide (LSD),
3 or an analog thereof;

4 (7.5) (i) 5 grams or more but less than 15 grams of any
5 substance listed in paragraph (1), (2), (2.1), (2.2), (3),
6 (14.1), (19), (20), (20.1), (21), (25), or (26) of
7 subsection (d) of Section 204, or an analog or derivative
8 thereof, or (ii) more than 10 pills, tablets, caplets,
9 capsules, or objects but less than 15 pills, tablets,
10 caplets, capsules, or objects containing in them or having
11 upon them any amount of any substance listed in paragraph
12 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
13 (21), (25), or (26) of subsection (d) of Section 204, or an
14 analog or derivative thereof;

15 (8) 10 grams or more but less than 30 grams of any
16 substance containing pentazocine or any of the salts,
17 isomers and salts of isomers of pentazocine, or an analog
18 thereof;

19 (9) 10 grams or more but less than 30 grams of any
20 substance containing methaqualone or any of the salts,
21 isomers and salts of isomers of methaqualone, or an analog
22 thereof;

23 (10) 10 grams or more but less than 30 grams of any
24 substance containing phencyclidine or any of the salts,
25 isomers and salts of isomers of phencyclidine (PCP), or an
26 analog thereof;

1 (10.5) 10 grams or more but less than 30 grams of any
2 substance containing ketamine or any of the salts, isomers
3 and salts of isomers of ketamine, or an analog thereof;

4 (10.6) 50 grams or more but less than 100 grams of any
5 substance containing hydrocodone, or any of the salts,
6 isomers and salts of isomers of hydrocodone, or an analog
7 thereof;

8 (10.7) (blank); ~~50 grams or more but less than 100~~
9 ~~grams of any substance containing dihydrocodeinone, or any~~
10 ~~of the salts, isomers and salts of isomers of~~
11 ~~dihydrocodeinone, or an analog thereof;~~

12 (10.8) 50 grams or more but less than 100 grams of any
13 substance containing dihydrocodeine, or any of the salts,
14 isomers and salts of isomers of dihydrocodeine, or an
15 analog thereof;

16 (10.9) 50 grams or more but less than 100 grams of any
17 substance containing oxycodone, or any of the salts,
18 isomers and salts of isomers of oxycodone, or an analog
19 thereof;

20 (11) 50 grams or more but less than 200 grams of any
21 substance containing a substance classified in Schedules I
22 or II, or an analog thereof, which is not otherwise
23 included in this subsection.

24 (c-5) (Blank).

25 (d) Any person who violates this Section with regard to any
26 other amount of a controlled or counterfeit substance

1 containing ~~dihydrocodeinone or~~ dihydrocodeine or classified in
2 Schedules I or II, or an analog thereof, which is (i) a
3 narcotic drug, (ii) lysergic acid diethylamide (LSD) or an
4 analog thereof, (iii) any substance containing amphetamine or
5 fentanyl or any salt or optical isomer of amphetamine or
6 fentanyl, or an analog thereof, or (iv) any substance
7 containing N-Benzylpiperazine (BZP) or any salt or optical
8 isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
9 guilty of a Class 2 felony. The fine for violation of this
10 subsection (d) shall not be more than \$200,000.

11 (d-5) (Blank).

12 (e) Any person who violates this Section with regard to any
13 other amount of a controlled substance other than
14 methamphetamine or counterfeit substance classified in
15 Schedule I or II, or an analog thereof, which substance is not
16 included under subsection (d) of this Section, is guilty of a
17 Class 3 felony. The fine for violation of this subsection (e)
18 shall not be more than \$150,000.

19 (f) Any person who violates this Section with regard to any
20 other amount of a controlled or counterfeit substance
21 classified in Schedule III is guilty of a Class 3 felony. The
22 fine for violation of this subsection (f) shall not be more
23 than \$125,000.

24 (g) Any person who violates this Section with regard to any
25 other amount of a controlled or counterfeit substance
26 classified in Schedule IV is guilty of a Class 3 felony. The

1 fine for violation of this subsection (g) shall not be more
2 than \$100,000.

3 (h) Any person who violates this Section with regard to any
4 other amount of a controlled or counterfeit substance
5 classified in Schedule V is guilty of a Class 3 felony. The
6 fine for violation of this subsection (h) shall not be more
7 than \$75,000.

8 (i) This Section does not apply to the manufacture,
9 possession or distribution of a substance in conformance with
10 the provisions of an approved new drug application or an
11 exemption for investigational use within the meaning of Section
12 505 of the Federal Food, Drug and Cosmetic Act.

13 (j) (Blank).

14 (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17.)

15 (720 ILCS 570/402) (from Ch. 56 1/2, par. 1402)

16 Sec. 402. Except as otherwise authorized by this Act, it is
17 unlawful for any person knowingly to possess a controlled or
18 counterfeit substance or controlled substance analog. A
19 violation of this Act with respect to each of the controlled
20 substances listed herein constitutes a single and separate
21 violation of this Act. For purposes of this Section,
22 "controlled substance analog" or "analog" means a substance,
23 other than a controlled substance, which is not approved by the
24 United States Food and Drug Administration or, if approved, is
25 not dispensed or possessed in accordance with State or federal

1 law, and that has a chemical structure substantially similar to
2 that of a controlled substance in Schedule I or II, or that was
3 specifically designed to produce an effect substantially
4 similar to that of a controlled substance in Schedule I or II.
5 Examples of chemical classes in which controlled substance
6 analogs are found include, but are not limited to, the
7 following: phenethylamines, N-substituted piperidines,
8 morphinans, ecgonines, quinazolinones, substituted indoles,
9 and arylcycloalkylamines. For purposes of this Act, a
10 controlled substance analog shall be treated in the same manner
11 as the controlled substance to which it is substantially
12 similar.

13 (a) Any person who violates this Section with respect to
14 the following controlled or counterfeit substances and
15 amounts, notwithstanding any of the provisions of subsections
16 (c) and (d) to the contrary, is guilty of a Class 1 felony and
17 shall, if sentenced to a term of imprisonment, be sentenced as
18 provided in this subsection (a) and fined as provided in
19 subsection (b):

20 (1) (A) not less than 4 years and not more than 15
21 years with respect to 15 grams or more but less than
22 100 grams of a substance containing heroin;

23 (B) not less than 6 years and not more than 30
24 years with respect to 100 grams or more but less than
25 400 grams of a substance containing heroin;

26 (C) not less than 8 years and not more than 40

1 years with respect to 400 grams or more but less than
2 900 grams of any substance containing heroin;

3 (D) not less than 10 years and not more than 50
4 years with respect to 900 grams or more of any
5 substance containing heroin;

6 (2) (A) not less than 4 years and not more than 15
7 years with respect to 15 grams or more but less than
8 100 grams of any substance containing cocaine;

9 (B) not less than 6 years and not more than 30
10 years with respect to 100 grams or more but less than
11 400 grams of any substance containing cocaine;

12 (C) not less than 8 years and not more than 40
13 years with respect to 400 grams or more but less than
14 900 grams of any substance containing cocaine;

15 (D) not less than 10 years and not more than 50
16 years with respect to 900 grams or more of any
17 substance containing cocaine;

18 (3) (A) not less than 4 years and not more than 15
19 years with respect to 15 grams or more but less than
20 100 grams of any substance containing morphine;

21 (B) not less than 6 years and not more than 30
22 years with respect to 100 grams or more but less than
23 400 grams of any substance containing morphine;

24 (C) not less than 6 years and not more than 40
25 years with respect to 400 grams or more but less than
26 900 grams of any substance containing morphine;

1 (D) not less than 10 years and not more than 50
2 years with respect to 900 grams or more of any
3 substance containing morphine;

4 (4) 200 grams or more of any substance containing
5 peyote;

6 (5) 200 grams or more of any substance containing a
7 derivative of barbituric acid or any of the salts of a
8 derivative of barbituric acid;

9 (6) 200 grams or more of any substance containing
10 amphetamine or any salt of an optical isomer of
11 amphetamine;

12 (6.5) (blank);

13 (7) (A) not less than 4 years and not more than 15
14 years with respect to: (i) 15 grams or more but less
15 than 100 grams of any substance containing lysergic
16 acid diethylamide (LSD), or an analog thereof, or (ii)
17 15 or more objects or 15 or more segregated parts of an
18 object or objects but less than 200 objects or 200
19 segregated parts of an object or objects containing in
20 them or having upon them any amount of any substance
21 containing lysergic acid diethylamide (LSD), or an
22 analog thereof;

23 (B) not less than 6 years and not more than 30
24 years with respect to: (i) 100 grams or more but less
25 than 400 grams of any substance containing lysergic
26 acid diethylamide (LSD), or an analog thereof, or (ii)

1 200 or more objects or 200 or more segregated parts of
2 an object or objects but less than 600 objects or less
3 than 600 segregated parts of an object or objects
4 containing in them or having upon them any amount of
5 any substance containing lysergic acid diethylamide
6 (LSD), or an analog thereof;

7 (C) not less than 8 years and not more than 40
8 years with respect to: (i) 400 grams or more but less
9 than 900 grams of any substance containing lysergic
10 acid diethylamide (LSD), or an analog thereof, or (ii)
11 600 or more objects or 600 or more segregated parts of
12 an object or objects but less than 1500 objects or 1500
13 segregated parts of an object or objects containing in
14 them or having upon them any amount of any substance
15 containing lysergic acid diethylamide (LSD), or an
16 analog thereof;

17 (D) not less than 10 years and not more than 50
18 years with respect to: (i) 900 grams or more of any
19 substance containing lysergic acid diethylamide (LSD),
20 or an analog thereof, or (ii) 1500 or more objects or
21 1500 or more segregated parts of an object or objects
22 containing in them or having upon them any amount of a
23 substance containing lysergic acid diethylamide (LSD),
24 or an analog thereof;

25 (7.5) (A) not less than 4 years and not more than 15
26 years with respect to: (i) 15 grams or more but less

1 than 100 grams of any substance listed in paragraph
2 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
3 (20.1), (21), (25), or (26) of subsection (d) of
4 Section 204, or an analog or derivative thereof, or
5 (ii) 15 or more pills, tablets, caplets, capsules, or
6 objects but less than 200 pills, tablets, caplets,
7 capsules, or objects containing in them or having upon
8 them any amount of any substance listed in paragraph
9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10 (20.1), (21), (25), or (26) of subsection (d) of
11 Section 204, or an analog or derivative thereof;

12 (B) not less than 6 years and not more than 30
13 years with respect to: (i) 100 grams or more but less
14 than 400 grams of any substance listed in paragraph
15 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
16 (20.1), (21), (25), or (26) of subsection (d) of
17 Section 204, or an analog or derivative thereof, or
18 (ii) 200 or more pills, tablets, caplets, capsules, or
19 objects but less than 600 pills, tablets, caplets,
20 capsules, or objects containing in them or having upon
21 them any amount of any substance listed in paragraph
22 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
23 (20.1), (21), (25), or (26) of subsection (d) of
24 Section 204, or an analog or derivative thereof;

25 (C) not less than 8 years and not more than 40
26 years with respect to: (i) 400 grams or more but less

1 than 900 grams of any substance listed in paragraph
2 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
3 (20.1), (21), (25), or (26) of subsection (d) of
4 Section 204, or an analog or derivative thereof, or
5 (ii) 600 or more pills, tablets, caplets, capsules, or
6 objects but less than 1,500 pills, tablets, caplets,
7 capsules, or objects containing in them or having upon
8 them any amount of any substance listed in paragraph
9 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10 (20.1), (21), (25), or (26) of subsection (d) of
11 Section 204, or an analog or derivative thereof;

12 (D) not less than 10 years and not more than 50
13 years with respect to: (i) 900 grams or more of any
14 substance listed in paragraph (1), (2), (2.1), (2.2),
15 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
16 subsection (d) of Section 204, or an analog or
17 derivative thereof, or (ii) 1,500 or more pills,
18 tablets, caplets, capsules, or objects containing in
19 them or having upon them any amount of a substance
20 listed in paragraph (1), (2), (2.1), (2.2), (3),
21 (14.1), (19), (20), (20.1), (21), (25), or (26) of
22 subsection (d) of Section 204, or an analog or
23 derivative thereof;

24 (8) 30 grams or more of any substance containing
25 pentazocine or any of the salts, isomers and salts of
26 isomers of pentazocine, or an analog thereof;

1 (9) 30 grams or more of any substance containing
2 methaqualone or any of the salts, isomers and salts of
3 isomers of methaqualone;

4 (10) 30 grams or more of any substance containing
5 phencyclidine or any of the salts, isomers and salts of
6 isomers of phencyclidine (PCP);

7 (10.5) 30 grams or more of any substance containing
8 ketamine or any of the salts, isomers and salts of isomers
9 of ketamine;

10 (11) 200 grams or more of any substance containing any
11 substance classified as a narcotic drug in Schedules I or
12 II, or an analog thereof, which is not otherwise included
13 in this subsection.

14 (b) Any person sentenced with respect to violations of
15 paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
16 involving 100 grams or more of the controlled substance named
17 therein, may in addition to the penalties provided therein, be
18 fined an amount not to exceed \$200,000 or the full street value
19 of the controlled or counterfeit substances, whichever is
20 greater. The term "street value" shall have the meaning
21 ascribed in Section 110-5 of the Code of Criminal Procedure of
22 1963. Any person sentenced with respect to any other provision
23 of subsection (a), may in addition to the penalties provided
24 therein, be fined an amount not to exceed \$200,000.

25 (c) Any person who violates this Section with regard to an
26 amount of a controlled substance other than methamphetamine or

1 counterfeit substance not set forth in subsection (a) or (d) is
2 guilty of a Class 4 felony. The fine for a violation punishable
3 under this subsection (c) shall not be more than \$25,000.

4 (d) Any person who violates this Section with regard to any
5 amount of anabolic steroid is guilty of a Class C misdemeanor
6 for the first offense and a Class B misdemeanor for a
7 subsequent offense committed within 2 years of a prior
8 conviction.

9 (Source: P.A. 99-371, eff. 1-1-16.)